238 related articles for article (PubMed ID: 29563500)
21. Herpes virus microRNA expression and significance in serous ovarian cancer.
Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
23. nc886, a non-coding RNA and suppressor of PKR, exerts an oncogenic function in thyroid cancer.
Lee EK; Hong SH; Shin S; Lee HS; Lee JS; Park EJ; Choi SS; Min JW; Park D; Hwang JA; Johnson BH; Jeon SH; Kim IH; Lee YS; Lee YS
Oncotarget; 2016 Nov; 7(46):75000-75012. PubMed ID: 27612419
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA Control of TGF-β Signaling.
Suzuki HI
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29958433
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract][Full Text] [Related]
26. An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer.
Li J; Liang S; Yu H; Zhang J; Ma D; Lu X
Gynecol Oncol; 2010 Dec; 119(3):543-8. PubMed ID: 20869762
[TBL] [Abstract][Full Text] [Related]
27. Sphingosine kinase 1 is required for TGF-β mediated fibroblastto- myofibroblast differentiation in ovarian cancer.
Beach JA; Aspuria PJ; Cheon DJ; Lawrenson K; Agadjanian H; Walsh CS; Karlan BY; Orsulic S
Oncotarget; 2016 Jan; 7(4):4167-82. PubMed ID: 26716409
[TBL] [Abstract][Full Text] [Related]
28. Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage.
Anglesio MS; Wang Y; Yang W; Senz J; Wan A; Heravi-Moussavi A; Salamanca C; Maines-Bandiera S; Huntsman DG; Morin GB
J Pathol; 2013 Feb; 229(3):400-9. PubMed ID: 23132766
[TBL] [Abstract][Full Text] [Related]
29. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D
Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663
[TBL] [Abstract][Full Text] [Related]
30. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
[TBL] [Abstract][Full Text] [Related]
31. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
32. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
33. Recently identified drug resistance biomarkers in ovarian cancer.
Davidson B
Expert Rev Mol Diagn; 2016; 16(5):569-78. PubMed ID: 26895188
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor.
Liu X; Li G
Int J Clin Exp Pathol; 2015; 8(9):10605-14. PubMed ID: 26617770
[TBL] [Abstract][Full Text] [Related]
35. miRNA profiling along tumour progression in ovarian carcinoma.
Vaksman O; Stavnes HT; Kaern J; Trope CG; Davidson B; Reich R
J Cell Mol Med; 2011 Jul; 15(7):1593-602. PubMed ID: 20716115
[TBL] [Abstract][Full Text] [Related]
36. Smad-mediated regulation of microRNA biosynthesis.
Blahna MT; Hata A
FEBS Lett; 2012 Jul; 586(14):1906-12. PubMed ID: 22306316
[TBL] [Abstract][Full Text] [Related]
37. Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis.
Chen J; Wang Y; McMonechy MK; Anglesio MS; Yang W; Senz J; Maines-Bandiera S; Rosner J; Trigo-Gonzalez G; Grace Cheng SW; Kim J; Matzuk MM; Morin GB; Huntsman DG
J Pathol; 2015 Oct; 237(2):215-25. PubMed ID: 26033159
[TBL] [Abstract][Full Text] [Related]
38. Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma.
Yang SD; Jang SS; Han JA; Park HS; Kim JI
Yonsei Med J; 2016 Jul; 57(4):872-8. PubMed ID: 27189279
[TBL] [Abstract][Full Text] [Related]
39. [Progress in studies on the relationship between
Dicer and ovarian tumor].
Zhao H; Shao H; Ma J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Oct; 40(10):1156-60. PubMed ID: 26541853
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
